Lercanidipine-induced chylous ascites: Case report and literature review. Scientific Publication

Oct 2, 2017 | Magazine: Journal of Clinical of Pharmacy Therapeuthics

Basualdo JE (1), Rosado IA (1), Morales MI (2), Fernández-Ros N (1), Huerta A (1), Alegre F (1), Landecho MF (1), Lucena JF (1).

WHAT IS KNOWN AND OBJECTIVE:

Chylous ascites is a rare condition. The most frequent causes are lymphomas, solid malignancies, abdominal trauma and cirrhosis. Isolated case reports describe the relationship between calcium channel blockers (CCB) and chyloperitoneum. Lercanidipine is a third-generation dihydropyridine with low rate of adverse events. We describe a case of lercanidipine-induced chylous ascites.

CASE SUMMARY:

An 80-year-old white female with hypertension treated with lercanidipine, developed chylous ascites and abdominal pain after the dosage of the CCB was doubled. The initial suspicion was a hidden neoplasm, but after a thorough research, no apparent cause was detected and the symptoms resolved after the drug was suspended.

WHAT IS NEW AND CONCLUSION:

Calcium channel blockers should be considered as possible causes in cases of chyloperitoneum of unknown aetiology.

CITATION J Clin Pharm Ther. 2017 Oct;42(5):638-641. doi: 10.1111/jcpt.12555

see publication in pubmed